Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrapulmonary PK of SPR720 in Healthy Volunteers
NCT05955586Phase 1Completed
- Sponsor
- Spero Therapeutics
- Start
- Aug 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fobrepodacin in nontuberculous mycobacterial pulmonary disease (NTM-PD), sponsored by Spero Therapeutics. Primary endpoints: Area Under the Concentration-time Curve from Time Zero to 24 Hours, Maximum Observed Concentration at Day 8 and 1 more. Started Aug 2023; status: completed.
02
Drugs
fobrepodacin
03
Conditions
nontuberculous mycobacterial pulmonary disease (NTM-PD)
Beyond the preview
Go deeper on NCT05955586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05955586.